Novartis to buy Avidity Biosciences for $12bn

Novartis to buy Avidity Biosciences for $12bn

Deal for specialist in rare diseases is biggest acquisition under chief executive Vas Narasimhan

Leave a Reply

Your email address will not be published. Required fields are marked *

Page Reader Press Enter to Read Page Content Out Loud Press Enter to Pause or Restart Reading Page Content Out Loud Press Enter to Stop Reading Page Content Out Loud Screen Reader Support
WordPress Cookie Plugin by Real Cookie Banner